首页|热毒宁注射液不良反应325例分析

热毒宁注射液不良反应325例分析

扫码查看
目的 探讨热毒宁注射液不良反应发生的规律及特点,为临床合理用药提供依据。方法 对2012年1月至2022年12月武汉市药品不良反应监测中心数据库中收集的325例热毒宁注射液药物不良反应(ADR)报告进行统计分析。结果 325例热毒宁注射液ADR报告中,6岁以下儿童发生ADR居多,多数为联合用药(52。62%);不合理用药导致ADR的影响因素为用药剂量不合理(14。77%)、超适应证用药(1。54%)、溶媒不合理(1。54%);ADR主要发生在用药30 min内,累及系统-器官与临床表现主要为皮肤及其附件损害(52。71%),全身性损害次之(21。26%)。结论 临床上需加强儿童病人(尤其是6岁以下)使用热毒宁注射液的ADR风险管理,应尽量避免循证医学证据不足的超剂量用药、超适应证及联合用药等不合理使用,避免增加ADR发生风险,保障热毒宁注射液的安全有效使用。
Analysis of 325 cases of adverse drug reaction of Reduning injection
Objective To investigate the rules and characteristics of adverse drug reactions(ADR)of Reduning injection,so as to pro-vide evidence for clinical rational drug use.Methods Three hundred and twenty-five cases of ADR related to Reduening injection which were collected from January 2012 to December 2022 based on database of Center for ADR Monitoring of Wuhan city were ana-lyzed statistically.Results In 325 cases of Reduning injection ADR,the majority of ADR occurred in children under 6 years old,most of which were combined medication(52.62%).The influencing factors of irrational drug use leading to ADR were unreasonable dose(14.77%),off-label drug use(1.54%)and unreasonable solvent(1.54%).ADR mainly occurred within 30 min of medication,and the main systematic-organ and clinical manifestations were skin and accessory damage(52.71%),followed by systemic damage(21.26%).Conclusion In clinical practice,it is necessary to strengthen ADR risk management of Reduning injection in children(especially un-der 6 years old),and avoid unreasonable use of excessive dosage,off-label and combined drug use with insufficient evidence of evi-dence-based medicine,so as to avoid increasing the risk of ADR and ensure the safe and effective use of Reduning injection.

Drug-related side effects and adverse reactionsAntiviral agentsDrugs,Chinese herbalReduning injectionSafe medicationAnalysis

江莹、张锦文、何艳、漆建军、柳莹、何凯霞、姜淑君

展开 >

武汉市药品不良反应监测中心,湖北 武汉 430030

华中科技大学同济医学院附属同济医院,药学部,湖北 武汉 430030

华中科技大学同济医学院附属同济医院,中西医结合科,湖北 武汉 430030

药物相关性副作用和不良反应 抗病毒药 中草药 热毒宁注射液 安全用药 分析

2025

安徽医药
安徽省药学会

安徽医药

影响因子:1.941
ISSN:1009-6469
年,卷(期):2025.29(1)